Quantcast

Latest Ibritumomab tiuxetan Stories

2009-03-19 00:30:00

Company estimates sales of pixantrone, if approved, could potentially reach $1 billion by 2014 SEATTLE, March 19 /PRNewswire-FirstCall/ -- Craig Philips, President of Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) reviewed CTI's programs in a presentation at the 8th Annual WBBA Invest Northwest Conference on Wednesday, March 18th . Mr. Philips' highlights focused on CTI's pixantrone program for treatment of aggressive relapsed non-Hodgkin's lymphoma (NHL) and OPAXIO for treatment of...

2009-03-16 00:30:00

Net operating expenses decreased by 33% in 2008; Forecast cutting net operating expenses by approximately 50% in 2009 CTI expects to complete pixantrone NDA submission in Q2 2009 SEATTLE, March 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2008. Recent Events Met primary endpoint in the Phase III study of pixantrone in relapsed, aggressive...

2009-02-20 15:05:00

CTI to focus on Pixantrone and OPAXIO Approval and Commercialization SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and Spectrum established a joint venture in December 2008 to develop and commercialize Zevalin. At that time CTI contributed all of the Zevalin related...

2009-02-18 00:30:00

SEATTLE, Feb. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that updated safety and efficacy data from the phase III trial of pixantrone provides further support for a robust clinical benefit for pixantrone when used as single agent therapy in the treatment of multiple relapsed aggressive non-Hodgkin's lymphoma (NHL). On an intent-to-treat analysis, pixantrone recipients who achieved a complete remission did so during the first 2 cycles of...

2009-02-10 00:30:00

SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to healthcare professionals for the treatment of individual patients with relapsing aggressive non-Hodgkin's lymphoma. This program is expected to be initiated by second quarter of 2009. "Under the...

2009-01-28 00:30:00

SEATTLE, Jan. 28 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (Nasdaq and MTA: CTIC) announced today preliminary progression-free survival (PFS) results from its pivotal phase III EXTEND (PIX301) trial of pixantrone that show patients with advanced, relapsed aggressive non-Hodgkin's lymphoma (NHL) treated with pixantrone experienced a statistically significant improvement in median progression-free survival, compared with other single-agent chemotherapeutic agents (4.7 months vs....

2009-01-22 00:30:00

SEATTLE, Jan. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today results of a study published by Esmaeli, et al. online on January 15, 2009 in the Annals of Oncology demonstrating that rituximab followed by single agent Zevalin (ibritumomab tiuxetan) in a front-line setting for patients with MALT lymphoma and low- grade follicular lymphoma that primarily involved the conjunctiva or orbit produced a complete response rate of 83 percent....

2009-01-14 00:30:00

SEATTLE, Jan. 14 /PRNewswire-FirstCall/ -- In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and 2008 accomplishments. CTI is seeking to obtain two new drug approvals in 2009 in addition to potential label expansion for Zevalin(R). In November CTI established a 50/50 joint venture with Spectrum Pharmaceuticals, Inc. (Spectrum) for Zevalin. "With a focus on...

2009-01-08 00:30:00

SEATTLE, Jan. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that they received $7.5 million pursuant to the joint venture transaction with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) in the United States. In December, the Company received the initial $7.5 million payment in connection with the closing of such transaction. The Company may earn up to an additional $15 million in product sales milestone payments upon...

2008-12-16 00:30:00

SEATTLE, Dec. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.(CTI) (Nasdaq and MTA: CTIC) announced today they have closed the transaction with Spectrum Pharmaceuticals, Inc. to form a 50/50 owned joint venture, RIT Oncology LLC (LLC), to commercialize and develop Zevalin(R) ([90Y]-ibritumomab tiuxetan) in the United States. In connection with the closing, Cell Therapeutics received an initial payment of $7.5 million and will receive an additional $7.5 million in early January. The...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related